Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.
Ontology highlight
ABSTRACT: Deferoxamine (DFO) is an FDA-approved iron-chelating agent which shows good therapeutic efficacy, however, its short blood half-life presents challenges such as the need for repeated injections or continuous infusions. Considering the lifelong need of chelating agents for iron overload patients, a sustained-release formulation that can reduce the number of chelator administrations is essential. Here, injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators are reported. The subcutaneously injected hydrogel shows a thermosensitive sol-gel transition at physiological body temperature and provides a prolonged release of renal clearable nanochelators over 2 weeks, resulting in a half-life 47-fold longer
SUBMITTER: Park SH
PROVIDER: S-EPMC9130884 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature
ACCESS DATA